...
首页> 外文期刊>Medical Devices: Evidence and Research >Variability in delivered dose and respirable delivered dose from nebulizers: are current regulatory testing guidelines sufficient to produce meaningful information?
【24h】

Variability in delivered dose and respirable delivered dose from nebulizers: are current regulatory testing guidelines sufficient to produce meaningful information?

机译:来自雾化器的输送剂量和可呼吸输送剂量的差异:当前的监管测试指南是否足以产生有意义的信息?

获取原文
           

摘要

Background: To improve convenience to patients, there have been advances in the operation of nebulizers, resulting in fast treatment times and less drug lost to the environment. However, limited attention has been paid to the effects of these developments on the delivered dose (DD) and respirable delivered dose (RDD). Published pharmacopoeia and ISO testing guidelines for adult-use testing utilize a single breathing pattern, which may not be sufficient to enable effective comparisons between the devices. Materials and methods: The DD of 5 mg of salbutamol sulfate into adult breathing patterns with inhalation:exhalation (I:E) ratios between 1:1 and 1:4 was determined. Droplet size was determined by laser diffraction and RDD calculated. Nine different nebulizer brands with different modes of operation (conventional, venturi, breath-enhanced, mesh, and breath-activated) were tested. Results: Between the non-breath-activated nebulizers, a 2.5-fold difference in DD (~750–1,900 μg salbutamol) was found; with RDD, there was a more than fourfold difference (~210–980 μg). With increasing time spent on exhalation, there were progressive reductions in DD and RDD, with the RDD at an I:E ratio of 1:4 being as little as 40% of the dose with the 1:1 I:E ratio. The DD and RDD from the breath-activated mesh nebulizer were independent of the I:E ratio, and for the breath-activated jet nebulizer, there was less than 20% change in RDD between the I:E ratios of 1:1 and 1:4. Conclusion: Comparing nebulizers using the I:E ratio recommended in the guidelines does not predict relative performance between the devices at other ratios. There was significant variance in DD or RDD between different brands of non-breath-activated nebulizer. In future, consideration should be given to revision of the test protocols included in the guidelines, to reflect more accurately the potential therapeutic dose that is delivered to a realistic spectrum of breathing patterns.
机译:背景:为了提高对患者的便利性,雾化器的操作有所进步,从而缩短了治疗时间,减少了药物向环境的损失。但是,对这些进展对输送剂量(DD)和可呼吸输送剂量(RDD)的影响只给予了有限的关注。针对成人使用测试的已发布药典和ISO测试指南采用了单一呼吸模式,这可能不足以实现设备之间的有效比较。材料和方法:确定5 mg硫酸沙丁胺醇在成人呼吸模式下的吸入/呼出(I:E)比为1:1至1:4的DD。通过激光衍射确定液滴尺寸并计算RDD。测试了9种不同的雾化器品牌,它们具有不同的操作模式(常规,文丘里管,呼吸增强,网状和呼吸激活)。结果:在非呼吸激活的雾化器之间,发现DD的差异为2.5倍(〜750–1,900μg沙丁胺醇)。使用RDD时,差异超过四倍(〜210–980μg)。随着呼气时间的增加,DD和RDD逐渐减少,I:E比为1:4的RDD仅为I:E比为1:1的剂量的40%。呼吸激活的网状雾化器的DD和RDD与I:E比率无关,对于呼吸激活的喷射雾化器,I:E比率1:1和1之间的RDD变化小于20%。 :4。结论:使用指南中推荐的I:E比率比较雾化器无法预测其他比率下设备之间的相对性能。不同品牌的非呼吸激活雾化器之间的DD或RDD差异很大。将来,应考虑对指南中包括的测试方案进行修订,以更准确地反映实际呼吸模式范围内的潜在治疗剂量。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号